Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
320last 24h
2133last 7d
379● bullish (7d)
186● bearish (7d)
204publishers
Insider Monkey46d agobullish
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBCStocktwits82d agobullish
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV TreatmentU.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.